Search

Your search keyword '"Gaich, Carol L."' showing total 21 results
Start Over Author "Gaich, Carol L."
21 results on '"Gaich, Carol L."'

9. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial

Author

Taylor, Peter C., primary, Lee, Yvonne C., additional, Fleischmann, Roy, additional, Takeuchi, Tsutomu, additional, Perkins, Elizabeth L., additional, Fautrel, Bruno, additional, Zhu, Baojin, additional, Quebe, Amanda K., additional, Gaich, Carol L., additional, Zhang, Xiang, additional, Dickson, Christina L., additional, Schlichting, Douglas E., additional, Patel, Himanshu, additional, Durand, Frederick, additional, and Emery, Paul, additional

Published
2019
Full Text
View/download PDF

10. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

Author

Tanaka, Yoshiya, primary, Fautrel, Bruno, additional, Keystone, Edward C, additional, Ortmann, Robert A, additional, Xie, Li, additional, Zhu, Baojin, additional, Issa, Maher, additional, Patel, Himanshu, additional, Gaich, Carol L, additional, de Bono, Stephanie, additional, Rooney, Terence P, additional, and Taylor, Peter C, additional

Published
2019
Full Text
View/download PDF

11. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD)

Author

Shi, Qiang, primary, Li, Ko-Jen, additional, Treuer, Tamas, additional, Wang, Bruce C. M., additional, Gaich, Carol L., additional, Lee, Chien-Hsun, additional, Wu, Wen-Shuo, additional, Furnback, Wesley, additional, and Tang, Chao-Hsiun, additional

Published
2018
Full Text
View/download PDF

14. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

Author

Schiff, Michael, primary, Takeuchi, Tsutomu, additional, Fleischmann, Roy, additional, Gaich, Carol L., additional, DeLozier, Amy M., additional, Schlichting, Douglas, additional, Kuo, Wen-Ling, additional, Won, Ji-Eon, additional, Carmack, Tara, additional, Rooney, Terence, additional, Durez, Patrick, additional, Shaikh, Saeed, additional, Hidalgo, Rodolfo Pardo, additional, van Vollenhoven, Ronald, additional, and Zerbini, Cristiano A. F., additional

Published
2017
Full Text
View/download PDF

15. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

Author

Emery, Paul, primary, Blanco, Ricardo, additional, Maldonado Cocco, Jose, additional, Chen, Ying-Chou, additional, Gaich, Carol L, additional, DeLozier, Amy M, additional, de Bono, Stephanie, additional, Liu, Jiajun, additional, Rooney, Terence, additional, Chang, Cecile Hsiao-Chun, additional, and Dougados, Maxime, additional

Published
2017
Full Text
View/download PDF

16. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

Author

Smolen, Josef S, primary, Kremer, Joel M, additional, Gaich, Carol L, additional, DeLozier, Amy M, additional, Schlichting, Douglas E, additional, Xie, Li, additional, Stoykov, Ivaylo, additional, Rooney, Terence, additional, Bird, Paul, additional, Sánchez Bursón, Juan Miguel, additional, Genovese, Mark C, additional, and Combe, Bernard, additional

Published
2016
Full Text
View/download PDF

17. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.

Author

Yoshiya Tanaka, Fautrel, Bruno, Keystone, Edward C., Ortmann, Robert A., Li Xie, Baojin Zhu, Issa, Maher, Patel, Himanshu, Gaich, Carol L., de Bono, Stephanie, Rooney, Terence P., Taylor, Peter C., Tanaka, Yoshiya, Xie, Li, and Zhu, Baojin

Abstract

Objective: To evaluate clinical outcomes in patients who changed treatment from adalimumab to baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, during a phase III programme.Methods: In phase III RA-BEAM, patients were randomised 3:3:2 to placebo, baricitinib 4 mg once daily, or adalimumab 40 mg biweekly. At week 16 or subsequent visits, non-responders were rescued to open-label baricitinib 4 mg. At week 52, patients could enter a long-term extension (LTE) and continue on baricitinib or switch from adalimumab to baricitinib 4 mg with no adalimumab washout period. Percentage of patients achieving low disease activity and remission were assessed, along with physical function, patient's assessment of pain, and safety.Results: Thirty-five (7%) baricitinib-treated and 40 (12%) adalimumab-treated patients were rescued to baricitinib in RA-BEAM; 78% (381/487) of baricitinib-treated and 72% (238/330) of adalimumab-treated patients who were not rescued in RA-BEAM, entered the LTE and continued/were switched to baricitinib. In both baricitinib-rescued and adalimumab-rescued patients, there were significant improvements in all measures up to 12 weeks after rescue compared with the time of rescue. Patients who switched from adalimumab to baricitinib showed improvements in disease control through 12 weeks in the LTE. Exposure-adjusted incidence rates for treatment-emergent adverse events (TEAEs) and infections, including serious events, were similar for patients who switched from adalimumab to baricitinib and those who continued on baricitinib.Conclusions: Switching from adalimumab to baricitinib (without adalimumab washout) was associated with improvements in disease control, physical function and pain during the initial 12 weeks postswitch, without an increase in TEAEs, serious adverse events or infections.Trial Registration Numbers: NCT01710358, NCT01885078. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

21. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

Author

Bernard Combe, Amy M. DeLozier, Joel M. Kremer, Li Xie, Josef S Smolen, Ivaylo Stoykov, Mark C. Genovese, Terence Rooney, Paul Bird, Juan Sanchez Burson, Douglas E Schlichting, Carol L. Gaich, [Smolen, Josef S.] Med Univ Vienna, Vienna, Austria, [Smolen, Josef S.] Hietzing Hosp, Vienna, Austria, [Kremer, Joel M.] Albany Med Coll, Albany, NY 12208 USA, [Gaich, Carol L.] Eli Lilly & Co, Indianapolis, IN 46285 USA, [DeLozier, Amy M.] Eli Lilly & Co, Indianapolis, IN 46285 USA, [Schlichting, Douglas E.] Eli Lilly & Co, Indianapolis, IN 46285 USA, [Xie, Li] Eli Lilly & Co, Indianapolis, IN 46285 USA, [Stoykov, Ivaylo] Eli Lilly & Co, Indianapolis, IN 46285 USA, [Rooney, Terence] Eli Lilly & Co, Indianapolis, IN 46285 USA, [Bird, Paul] Univ New South Wales, Sydney, NSW, Australia, [Sanchez Burson, Juan Miguel] Valme Univ Hosp, Div Rheumatol, Seville, Spain, [Sanchez Burson, Juan Miguel] Valme Univ Hosp, Div Ophthalmol, Seville, Spain, [Sanchez Burson, Juan Miguel] Valme Univ Hosp, Div Immunol, Seville, Spain, [Genovese, Mark C.] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA, [Combe, Bernard] Univ Montpellier, Lapeyronie Hosp, Montpellier, France, Eli Lilly and Company, Incyte Corporation, Medizinische Universität Wien = Medical University of Vienna, Albany Medical College, University of New South Wales [Sydney] (UNSW), Valme University Hospital, Stanford University Medical Center, Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Albany medical college, University of New South Wales [Sydney] ( UNSW ), Institut de Génétique Moléculaire de Montpellier ( IGMM ), and Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
Baricitinib, [SDV]Life Sciences [q-bio], Arthritis, Efficiency, DMARDs (biologic), Clinical-trials, Logistic regression, Severity of Illness Index, Arthritis, Rheumatoid, 0302 clinical medicine, Surveys and Questionnaires, Immunology and Allergy, 030212 general & internal medicine, Pain Measurement, Sulfonamides, Connective tissue disease, 3. Good health, Outcomes research, Rheumatoid arthritis, DMARDs (synthetic), Adult, medicine.medical_specialty, Immunology, Rheumatoid Arthritis, Placebo, General Biochemistry, Genetics and Molecular Biology, Patient perspective, Abatacept, 03 medical and health sciences, Young Adult, Rheumatology, Double-Blind Method, Internal medicine, Disease-activity, medicine, Improvement, Humans, Necrosis-factor inhibitors, In patient, Patient Reported Outcome Measures, Protein Kinase Inhibitors, 030203 arthritis & rheumatology, [ SDV ] Life Sciences [q-bio], business.industry, Questionnaire, Presenteeism, Clinical and Epidemiological Research, medicine.disease, Methotrexate, Purines, Tofacitinib, Physical therapy, Quality of Life, Azetidines, Pyrazoles, Quality-of-life, Therapy, business
Abstract

Objectives To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to >= 1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs).Methods In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4 mg for 24 weeks. PROs included the Short Form36, EuroQol 5-D, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, duration of morning joint stiffness (MJS) and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis. Treatment comparisons were performed with logistic regression for categorical measures or analysis of covariance for continuous variables.Results 527 patients were randomised (placebo, 176; baricitinib 2 mg, 174; baricitinib 4 mg, 177). Both baricitinib-treated groups showed statistically significant improvements versus placebo in most PROs. Improvements were generally more rapid and of greater magnitude for patients receiving baricitinib 4 mg than 2 mg and were maintained to week 24. At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (HAQ-DI = 1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs).Methods In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4 mg for 24 weeks. PROs included the Short Form36, EuroQol 5-D, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, duration of morning joint stiffness (MJS) and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis. Treatment comparisons were performed with logistic regression for categorical measures or analysis of covariance for continuous variables.Results 527 patients were randomised (placebo, 176; baricitinib 2 mg, 174; baricitinib 4 mg, 177). Both baricitinib-treated groups showed statistically significant improvements versus placebo in most PROs. Improvements were generally more rapid and of greater magnitude for patients receiving baricitinib 4 mg than 2 mg and were maintained to week 24. At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (HAQ-DI = 3.56; p

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results